Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of ...
2h
Van Ness, 37, turned to a weight loss medication to assist him in his efforts, and clearly all his hard work and dedication ...
Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...
On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.
Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Jonathan Van Ness is “so proud” of themself after losing 66 lbs. The Queer Eye star, 37, took to their Instagram Story on Sunday, Feb. 23 to share a before and after shot of their recent weight loss ...
AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. Click here to find out ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
It’s hard to watch television without seeing advertisements for compounded GLP-1 weight-loss drugs cheaper than the authentic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback